Prime Medicine (PRME) Shares Outstanding (2021 - 2026)

Prime Medicine (PRME) has 6 years of Shares Outstanding data on file, last reported at $180.6 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 37.71% year-over-year to $180.6 million; the trailing twelve-month figure through Mar 2026 stood at $180.6 million (up 37.71% YoY), and the FY2025 full-year result was $180.5 million, up 37.63% from the prior year.
• Shares Outstanding for Q1 2026 stood at $180.6 million, roughly flat from $180.5 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $180.6 million in Q1 2026 and bottomed at $33.5 million in Q2 2022.
• The 5-year median for Shares Outstanding is $120.0 million (2024), against an average of $111.6 million.
• The widest annual swing landed in 2022, when Shares Outstanding soared 199.9%; it then advanced 0.17% in 2023.
• A 5-year view of Shares Outstanding shows it stood at $97.2 million in 2022, then grew by 0.17% to $97.4 million in 2023, then soared by 34.69% to $131.2 million in 2024, then soared by 37.63% to $180.5 million in 2025, then advanced by 0.06% to $180.6 million in 2026.
• The last three Shares Outstanding figures came in at $180.6 million (Q1 2026), $180.5 million (Q4 2025), and $180.3 million (Q3 2025), per Business Quant data.

Peer Comparison